Meta-analysis · people
Thymosin alpha-1: lower COVID-19 death risk (RR 0.59) in meta-analysis
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Pooled data tie thymosin alpha-1 to fewer COVID-19 deaths in moderate to critical illness, but not to less ventilator use or shorter hospital stays, and the authors call for randomized trials to confirm it.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2023
- Journal
- Inflammopharmacology
What they tested
The team set out to test whether thymosin alpha-1 helps people with moderate to severe COVID-19.
How the study was done
A systematic review and meta-analysis, which pools results from earlier studies. It combined data from 8 studies of people with moderate to critical COVID-19 who got thymosin alpha-1, compared with placebo, a dummy treatment.

What they found
Across the 8 studies, people given thymosin alpha-1 had a lower risk of dying from COVID-19, with a risk ratio of 0.59 (95% CI 0.37-0.93, p = 0.02). A risk ratio below 1 means lower risk in the treated group. There was no difference in the need for mechanical ventilation, a breathing machine (RR 0.83; 95% CI 0.48-1.44), or in hospital length of stay (mean difference 2.32; 95% CI -0.93 to 5.58). The death result was shaped by the size of each study and by sex.
What it doesn’t show
The pooled studies differed a lot from each other (I2 of 84% for the death result), and the effect depended on study size and sex. The authors say randomized trials are still needed to confirm the finding.
The paper
Soeroto et al. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023.
The compound
More studies on Thymosin Alpha-1
- Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-upMeta-analysis · people · 2008
- Thymosin alpha-1 lowered infections after colorectal cancer surgeryRandomized trial · people · 2024
- Thymosin alpha-1: 3 deaths vs 7 in dialysis COVID-19 pilot so farRandomized trial · people · 2023
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
- Thymosin Alpha-1 combo: 47.8% viral response at 24 weeks in hep CClinical trial · people · 2004
- Every study on Thymosin Alpha-1
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.